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Clinicopathological spectrum of ovarian sex
cord-stromal tumors; 20 years’ retrospective study
in a developing country
Saroona Haroon1*, Aleena Zia2, Romana Idrees1, Aisha Memon1, Saira Fatima1 and Naila Kayani1
Abstract
Background: Ovarian sex cord stromal tumors are rare neoplasms as compared to epithelial tumors. No large
study has been done in Pakistan to find out the frequencies of various sex cord stromal tumors and their
clinicopathological behavior in our region. The purpose of our study was to determine the various histological
patterns and clinical features of ovarian sex cord stromal tumors along with follow-up in our set-up.
Methods: It is a retrospective observational study. The study was conducted in section of Histopathology, Aga
Khan University Hospital, Karachi, Pakistan. All reported cases of sex cord stromal tumors of ovary during 1992 to
2012 were retrieved. The retrieved slides were reviewed and patient demographics, clinical and pathological
features were noted on proforma. SPSS Statistics Version 19 was used for all analyses. Data is expressed as absolute
values and percentage or as mean ± standard deviation (SD).
Results: A total of 480 cases of sex cord stromal tumors were retrieved. The median age was 45 years. Bilaterality
was observed in 4 cases. Of the different subtypes of sex-cord stromal tumors, most common was adult granulosa
cell tumor 211(43.9%). 24 Juvenile granulosa cell tumors were retrieved (5%). Other types were fibromas 98 (20.4%)
fibrothecomas 47(9.8%), thecomas 26(5.4%), sertoli-leydig cell tumors 34(7%), sclerosing stromal tumors 26 (5.4%),
steroid cell tumors (10) and 4 cases of sex cord tumor with annular tubules. Of various immunohistochemical stains
applied, Inhibin was frequently positive in all subtypes and focal cytokeratins were also seen commonly. Follow up
information was available in 305 cases and out of these only 16 (5%) developed recurrence or metastasis.
Conclusions: Sex cord stromal tumors are uncommon ovarian tumors in Pakistani population, with wide age range
and diverse histological types having good prognosis. Immunohistochemical markers overlap with epithelial tumors
so there is need to distinguish these two.
Keywords: Sex cord stromal tumour, Granulosa cell tumour, Ovarian neoplasm
Background
Sex-cord stromal tumors (SCST) are subtype of ovarian
neoplasms that are relatively infrequent. These account for
only about 7% of all primary ovarian tumors. The sex cord
stromal tumors are most of the time low grade and present
generally in younger patients than ovarian epithelial malig-
nancies [1]. They encompass a heterogeneous group of
neoplasms containing variety of cells which are derived
from gonadal sex cords or stromal cells [2]. Because of the
smaller size, lower grade of malignancy and the rarity of
these tumors, they are often diagnosed by pathology
following surgery [3].
The morphology of these tumors varies and these can
simulate epithelial ovarian neoplasms or mesenchymal
tumors histologically to an extent of misdiagnosis [4].
Immunohistochemical staining may be useful for estab-
lishing the diagnosis in problematic cases due to varied
appearance and rarity [3,5]. Steroidenic factor 1 (SF 1) and
FOXL2, although not available in our set-up are useful
marker studied in recent times and is positive in lesions of
sex cord-stromal differentiation. Although some of these
tumors are Cytokeratin (CK) AE1/AE3 positive, epithelial
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membrane antigen (EMA) negativity may be useful for the
differential diagnosis with epithelial ovarian tumors [6].
Furthermore these tumors can show somewhat fas-
cinating behavior profile with the fluctuating clinical
presentations of precocious puberty to menorrhagia to
postmenopausal bleeding [7].
Primary treatment is surgery, which is conservative for
stage-1 tumors. Treatment for advanced or recurrent
disease includes primary or adjuvant chemotherapy.
Majority of these tumors are of low malignant potential
and are associated with favorable prognosis [8].
We performed the research to analyze the frequencies
and clinicopathological spectrum along with follow up
of ovarian sex cord stromal tumors in our center, which
is one of the largest referral centers for histopathology
specimens in Pakistan.
Methods
We performed a retrospective analysis of all patients
diagnosed with ovarian sex cord stromal tumors from
January 1, 1992 to December 31, 2012, whose specimens
were received at Histopathology section, Department of
Pathology and Microbiology, Aga Khan University Hospital,
Karachi. Patients were identified from a prospectively main-
tained departmental database, Integrated Lab. Management
System, with keywords search. As this is an observational
study and the confidentiality was thoroughly maintained,
ethical review committee’s approval was not required,
which is mandatory in experimental research according to
Helniski’s declaration.
Ovarian sex cord stromal tumors were diagnosed
according to defined morphology and immunohisto-
chemistry. More specifically, granulosa cell tumors (both
juvenile and adult types), fibromas, thecomas, sclerosing
stromal tumors, sex cord tumor with annular tubules,
Sertoli-leydig cell tumors, steroid cell tumors or mixture
of these were included in this study. For patients that
presented with recurrence, slides from the initial specimen
(if available) were reviewed to confirm the diagnosis.
Following high laboratorial quality control systems,
Five-micrometer thick sections were used for the im-
munohistochemistry studies. The tissue samples were
processed by conventional methods, including overnight
fixation in 10% formalin and subsequent embedding in
paraffin.
The most representative blocks were used and stained
with haematoxylin and eosin. Immunohistochemical as-
sessment was carried out using the avidin–biotin immu-
noperoxidase technique. The primary antibodies used in
the study are outlined in Table 1. Relevant cytoplasmic
and/or membranous staining by antibodies was taken as
positive according to established criteria.
We excluded patients where differential diagnosis was
given, due to non-convincing histology and/or subopti-
mal immunostaining. Electronic medical records were
reviewed for age at diagnosis, surgical procedures per-
formed, site of tumor and type of tumor. Surgical stage
was determined from pathologic records at the time of
diagnosis, when available. Complete staging was defined
as at least a unilateral salpingo-oophorectomy, pelvic
washings, peritoneal biopsies, omental sampling, and pel-
vic and para-aortic lymph nodal sampling. Surgical stage
based on the International Federation of Gynecology and
Obstetrics (FIGO) 1988 criteria was compared to the
recent FIGO 2009 staging criteria modifications. Staging
procedures were predominantly done for clinically suspi-
cious and per-operatively malignant cases. Few patients
whose surgery was performed in our own centre or in
vicinity had intra-operative frozen section.
For the present study, all relevant data were retrieved
from our database into a separate anonymous database.
In this separate database, patient identity was protected
by a study-specific, unique patient code, which was
known only to two of the authors (SH and AZ).
This is a single center retrospective case series. SPSS
Statistics Version 19 was used for all analyses. Data are
Table 1 Common antibodies used in the study
Antibody Clone Species Antibody source Dilution
Inhibin R1 Monoclonal Mouse Anti-Human Dako Denmark 1:50
Actin (Smooth Muscle) 1A4 Monoclonal Mouse Anti-Human Dako Denmark 1:250
Vimentin Vim 3B4 Monoclonal Mouse Anti-Human Dako Denmark 1:100
CD 99, mic-2 12E7 Monoclonal Mouse Anti-Human Dako Denmark Pre-diluted
Cytokeratin AE1/AE3 Monoclonal Mouse Anti-Human Dako Denmark 1:50
Calretinin DAK-Calret 1 Monoclonal Mouse Anti-Human Dako Denmark 1:100
Epithelial Membrane Antigen (EMA) E29 Monoclonal Mouse Anti-Human Dako Denmark 1:50
Cytokeratin 7 OV-TL 12/30 Monoclonal Mouse Anti-Human Dako Denmark 1:100
CD117, c-kit - Polyclonal Rabbit Anti-Human Dako Denmark 1:100
Desmin D33 Monoclonal Mouse Anti-Human Dako Denmark 1:150
Cytokeratin CAM 5.2 Monoclonal Mouse Anti-Human Becton, Dickinson and Company, NJ Pre-diluted
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expressed as absolute values and percentage or as
mean ± standard deviation (SD).
Results
A total of 480 patients with ovarian sex cord stromal
tumors were included with a median age of 45 years.
The age ranged from 1 to 92 years with mean ± SD was
44.3 ± 16.8 years. The right ovary was involved in 199
cases (55.1%) and left in 162 cases (44.9%), Bilaterality
was observed in 4 cases. In the rest of cases, information
regarding laterality was missing. Abdominal lump with
pain (67%) and abdominal distension (54%) were the
most common symptoms (Table 2).
Granulosa cell tumor, adult type
Of the different types of sex-cord stromal tumors adult
granulosa cell tumor (AGCT) was most common sub-
type amounting to total number of 211(43.9%). Age
range was 19 to 90 years with median age of 48 years.
Right sided ovary was slightly more involved (81 cases)
than left sided ovary (71 cases). Most of the tumors had
solid and partially cystic hemorrhagic surface with tumor
cells having typical coffee bean nuclei on light micros-
copy (Figure 1).
Detailed immunohistochemical analysis was done in
163 cases, which showed all of granulosa cell tumors
positive for Inhibin, majority i.e. approximately 90%
were positive for calretinin (n = 147) , 68% were positive
for CD99 (n = 111), and a large number approximately
60% were also weak focal positive for Cytokeratins (n = 98).
Twenty four granulosa cell tumors were associated
with simple endometrial hyperplasia without atypia.
Three of the granulosa cell tumors were associated with
endometrial carcinoma and one with endometrial hyper-
plasia with atypia and one with endometrial polyp.
Total 13 cases showed metastasis or the tissue received
was from sites adjacent to ovary. Out of which ten invol-
ved mesentery/omentum, one infiltrated small intestine
and one infiltrated large intestine. One even reached the
anterior abdominal wall. One cases surprisingly had syn-
chronous squamous cell carcinoma of cervix.
The various types of specimen reflecting the nature of
surgery performed in each kind sex cord stromal tumor
are listed in Table 3. Complete follow-up data of only 86
patients was available, with late recurrence in 5 cases (at
18, 23, 37, 41 and 52 months after initial diagnosis). Metas-
tasis was observed in 4 patients. 2 patients died of AGCT
(11 and 18 months respectively after initial diagnosis) and
2 patients died of some other illness. Rests of patients were
free of disease till the time of last follow up.
Granulosa cell tumor, juvenile type
Total 24 juvenile granulosa cell tumors (JGCT) were
diagnosed during this 20 year period. Immunohisto-
chemical analysis done in 20 cases showed negative ex-
pression of CKs. Follow up of only 11 cases was available,
and out of these 2 cases had recurrence (after 8 and
17 months of initial diagnosis) and one died of disease
(after 7 months).
Fibromas
Total 98 cases of fibromas were found. Age range was 12
to 79 years and mean was 42.2 years. Cellular fibromas
had mean size larger (14.5 cm) than those of fibromas
(8.7 cm). The gross appearance of fibromas showed
whorled tan white areas (Figure 1). 5 cases of mitotically
active cellular fibromas were retrieved along with seven
cases of cellular fibromas. Mitotically active cellular fibro-
mas had mean age of 46 years and mean size of 9.7 cm.
Follow up of 37 cases was available including 3 cases each
of mitotically active cellular fibroma and cellular fibroma.
Only one case of mitotically active cellular fibroma
showed recurrence, 14 months after initial surgery.
Thecomas
Out of 26 cases of thecomas, one case behaved in
aggressive fashion extending into the urinary bladder.
Right ovary was involved in 11 cases and left ovary in 12
cases (n = 23) The tumor presented at stage I, in all cases
except one in which tumor infiltrated the urinary
bladder wall, and only in this case, moderate atypia and
significant mitoses (3/10 HPF) were present. The slides
of this unusual case were reviewed and no granulosa
cell component was identified even with reticulin
stain. Follow up of 13 cases was obtainable and all the
patients were tumor free with mean follow up period of
94 months.
Table 2 Age distribution and frequencies of various
clinical signs and symptoms
Age of patient (years) Number of patients
<20 34
≥20-40 145
≥40-60 186
≥60-80 108
≥80 7
Presenting complaints
Asymptomatic 87
Lump with pain abdomen 218
Irregular bleeding per-vaginum 136
Postmenopausal bleeding 68
Secondary amenorrhea 10
Precocious puberty 7
Virilizing symptoms 39
Overlapping symptoms 81
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Fibrothecomas
Total 47 cases of fibrothecomas were recovered out of
which one was associated with endometrial hyperplasia
and one was found with carcinoma cervix. Age range was
2 years to 80 years and median age was 50 years. Right side
was more commonly involved in 28 cases and left in 12
cases. Two cases were bilateral. Follow up of 19 patients
was available and all the patients were alive and healthy.
Sertoli-leydig cell tumor
Total 34 cases of sertoli-leydig cell tumor (SLCT) were
found. Proper surgical staging was done in 19 tumors,
with 11 presenting at FIGO stage II or higher. Spectrum
of these tumors according to differentiation and the
information about tumor stage is given in Table 4.
Detailed follow up of only 12 cases was available and 2
patients developed metastasis and died of disease after 9
Figure 1 Gross and microscopic features of two most frequent SCSTs; Adult granulosa cell tumor and Fibroma. A) Gross appearance of
Adult granulosa cell tumor. B) Microscopic picture shows coffee bean nuclei of the tumor cells present in form of sheets. (Hemotoxylin and Eosin,
40×). C) Gross picture of Fibroma. D) Microscopy shows bland nuclei with scant cytoplasm. (Hemotoxylin and Eosin, 40×).
Table 3 Frequencies of various types of sex cord stromal tumors, median age and mean size
Type of tumor N (percentage) Median age
(in years)
Mean size
(in cms)
Types of specimen received
TAH-BSO USO BSO TAH-USO
Adult granulosa cell tumor 211 (43.9%) 48 10.8 121 23 17 32
Juvenile granulosa cell tumor 24 (5%) 19 15 7 5 3 5
Fibrothecoma 47 (9.8%) 50 10.9 15 21 4 3
Fibroma 98 (20.4%) 40 8.7 32 16 6 9
Thecoma 26 (5.4%) 52 8.5 6 8 2 2
Sertoli Leydig cell tumor 34 (7%) 30 15.4 10 6 2 1
Steroid cell tumor 10 (2%) 44 6.3
Sclerosing stromal tumor 26 (5.4%) 22.5 9.3 7 4 1 6
Sex cord tumor with annular tubules 4 (0.8%) 32.5 9
Abbreviations:
TAH-BSO Total abdominal hysterectomy and bilateral salpingo-oophorectomy.
USO Unilateral salpingo-oophorectomy.
BSO Bilateral salpingo-oophorectomy.
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and 23 months respectively despite Cisplatin based
chemotherapy.
Sclerosing stromal tumor
26 cases of sclerosing stromal tumor (SST) were diag-
nosed and 13 involved left ovary. Ten arose in right ovary
and information about side was missing in 3 cases. In all
cases except one, capsule was intact. Follow up of only 17
patients was available and no recurrence or metastasis
was seen with mean follow up period of 134 months.
Steroid cell tumors
Steroid cell tumors (SCT) were total 10 in number. All of
the tumors were stage-I at time of diagnosis. Additional
Immunohistochemical stain used was Melan A and WT-1
were positive in all of cases when applied. Follow up of 8
patients was available and one tumor recurred after
21 months of surgery.
Sex cord tumor with annular tubules
Sex cord stromal tumor with annular tubules was the
diagnosis in 4 cases, with a wide age range of 15 to
57 years. 2 tumours having detailed clinical history had
associated Peutz Jegher’s syndrome.
Bilateral tumors
Out of four bilateral cases, two were fibrothecomas, one
was AGCT and one was sertoli leydig cell tumor. No
two different tumors occurred bilaterally at same time.
Immunohistochemical analysis
Immunohistochemical studies were done in 241 patients
and most common panel used included Cytokeratin AE1/
AE3, Cytokeratin Cam 5.2, Calretinin, inhibin, WT1 and
Anti-Smooth Muscle Actin (ASMA). EMA was also used
(n = 121) and it was negative in all the cases, a very
important differentiating point.
Discussion
The SCSTs account for approximately 7% of all ovarian
tumors [1,3,4]. Although these usually present at youn-
ger age group, there is wide age range of presentation
and wider morphologic spectrum of these tumors [3,5].
The coexistence of two different types of sex-cord
stromal tumors is also extremely rare [9].
In Pakistan, little research has been done focusing on
epidemiology of ovarian sex cord stromal tumors. In this
retrospective analysis, we aimed to report the experience
with a large series of these rare tumors in a major
tertiary care center in Pakistan.
Most of the characteristics of our study population
were similar to those reported in the literature. The
commonest symptoms are abdominal pain and disten-
tion along with menstrual disturbances. However in our
study population, the hormonal changes were not very
frequently observed. In our series, just under half of
women were below the age of 50 at the time of diagnosis
and fertility sparing surgery is often desired among these
women. So the nature of specimen listed in Table 3 vary
according to the tumor type hence reflecting the median
age of patient at the time of diagnosis and the surgical
impression of malignancy intra-operatively. Moreover
there was little variation in size of tumors among the
sub-groups, hence did not correlate significantly with
the benign or malignant nature of tumor. In children,
the most frequent tumors were JGCTs followed by SST,
SLCT and fibrothecomas.
Newer entities were also encountered though less
frequently as reported in literature to date. Total 5 mito-
tically active cellular fibromas were found, exclusive of 7
cellular fibromas.
GCTs are sex-cord-stromal tumors that make up 70%
of all such tumors but in our study these tumors
comprised of 43.5% of all the sex cord stromal tumors
that were diagnosed during the study period. The granu-
losa cell tumors are divided into adult (95%) and juvenile
(5%) types based on specific diagnostic histological
findings; however our observation showed that juvenile
granulosa cell tumors were around 10% of all GCT
which is bit higher than reported in other large series.
The JGCT occurred in premenarchal girls and young
women [8-11].
Inhibin was positive in all the granulosa cell tumors.
Cytokeratin’s dot positivity was observed in most of the
Table 4 Sertoli-leydig cell tumors; frequencies of various types
Number of cases
(percentage)
Differentiation Surgical stage (FIGO)
Stage I Stage II or higher
3 (8.8%) Well differentiated (Meyer Type I) 2 -
15 (44.1%) Intermediate differentiated (Meyer Type II) 4 4
10 (29.4%) Poorly differentiated (Meyer Type III) 1 4
4 (11.8%) With heterologous elements (teratoid androblastoma) - 2
1 (2.9%) Retiform(“netlike”) 1 -
1 (2.9%) Metastatic - 1
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cases of AGCT (76.5%). In JGCTs, Cytokeratin negativity
was one of the major helpful features to rule our epithe-
lial malignancy despite greater nuclear pleomorphism
and mitotic activity than adult granulosa cell tumor.
Molecular analysis is also helpful in diagnosis of AGCT,
which was not available in our set-up. Complete follow-
up data of only 86 patients was available with mean
follow-up duration of 37 months. In our study popula-
tion, late recurrences with the granulosa cell tumors
were not infrequent, encountered in 5 patients, which
re-emphasizes the need for long term follow-up of these
patients [12-14]. When the disease could not be com-
pletely resected or recurred after surgical resection,
prognosis was poorer with 1 patients dying soon after
recurrence. Metastasis was observed at the time of pres-
entation in 13 of the cases and subsequent metastasis
was observed in 4 of patients.
Addition of Calretinin and WT-1 these two antibodies
was found to be quite useful in the diagnosis of ovarian
SCSTs in equivocal cases [12,14].
Among total 98 cases of fibromas, the mean age of
patients was in accord with the international data i.e.
42.2 years. Median age was 52, which was just slightly
lower than the international published data. The seven
Cellular fibromas had mean size of 14.5 cm, which is
larger than the previously reported studies. 5 cases of
mitotically active cellular fibromas had mean age of
46 years and mean size of 9.7 cm, which is comparable
to the past series [15,16]. One case of fibroma was asso-
ciated with carcinoma cervix and interestingly one case
each with carcinoma of endometrium and endometrial
hyperplasia, once again proving that these tumors are
hormonally active as were many thecomas because
endometrial pathology was present in 11 out of 26 cases
of thecomas. [16]. Calretinin proved to be more sensitive
than inhibin. In addition, we tested few of our subset of
fibromas with CD10, because ovarian endometrial stro-
mal sarcomas may have areas that resemble fibroma
[17]. Follow-up of 37 cases was available including 3
cases each of mitotically active cellular fibroma and
cellular fibroma. No metastasis was observed complying
to the benign nature of tumor, however one case of
mitotically active cellular fibroma recurred, 14 months
after surgery.
Most of the ovarian sex cord stromal tumors, in which
information regarding the FIGO stage was available, pre-
sented at Stage I. FIGO staging is the most important,
globally accepted, prognostic factor. Most of fibromas
and thecomas presented at stage I, in all cases except
one in which tumor infiltrated the urinary bladder wall,
and only in this case, moderate atypia and significant
mitoses (3/10 HPF) were present[18,19]. Most common
specimen received was unilateral oophorectomy, relating
to the clinically and radiologically benign nature of most
of the tumors. Predominantly only in granulosa cell
tumors and Sertoli Leydig cell tumors among our study
population, surgical staging procedures were done. And
this number was also very low, but owing to no nodal
metastasis in these cases, this might be appropriate. In
patients with SLCT where proper surgical staging pro-
cedure was done (n = 19), it was found that majority of
tumors (n = 11) presented at higher stage i.e. FIGO stage
IIA/IIB or higher. Although mostly these tumors present
at stage I, the probable explanation for presenting at
higher stage in our observation could be the very low
number of well-differentiated SLCT.
Total 34 cases of sertoli-leydig cell tumor were found.
Mean age 35.2 years. Mean size 15.4 cm. Poorly differen-
tiated were a little more frequent as compared to previ-
ous study data but SL tumor with heterologous elements
were somewhat less. [20-22].
SST is a very rare ovarian stromal tumour that was for
the first time described by Chalvardjian and Scully. 26
cases of sclerosing stromal tumor were diagnosed with
the mean age of 28.7 years, which was comparable to
other studies [23-26]. However age range was slightly
wider, 10 to 64 years. In all cases except one, capsule
was intact. Analysis of cut surface showed that most of
the cases had solid and cystic areas, however 4 cases had
entirely solid surface. The spindly cells were stained
strongly for both ASMA and desmin along with Inhibin
and theca like component stained positive with CD 99
and calretinin. Metastatic signet-ring cells were excluded
with the negative staining for keratin and EMA.
Steroid cell tumors were total 10 in number. Mean age
was 45.2 years, which was in accord with the previously
reported mean age for this tumor [20,21]. Most common
presentation was virilizing symptoms. Additional Immu-
nohistochemical stain used was Melan A, which was
positive in all of cases when applied. WT-1 was also
positive in all the cases. Cytokeratins were negative in all
the cases.
Sex cord stromal tumor with annular tubules was the
diagnosis in 4 cases, with a wide age range of 15 to
57 years. Two of the cases were found to be associated
with of Peutz-Jeghers Syndrome. In the other two cases,
adequate history was not available. Because of this miss-
ing data, the strong association between SCTAT and
Peutz-Jeghers Syndrome could not be re-substantiated.
Out of four bilateral cases, two were fibrothecomas,
one was AGCT and one was sertoli leydig cell tumor.
No two different sex cord stromal tumors occurred
bilaterally at same time, however 8 fibrothecoma group
tumors and 12 granulosa cell tumors were found to be
associated with contralateral ovarian cystadenofibroma.
To our knowledge, this is first kind of study of long
duration and large data set, addressing ovarian sex cord
stromal tumors in Pakistani population specifically. Also
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our set-up is one of the largest anatomical pathology
and oncology setup with laboratory specimen collection
centres all over Pakistan, so representation of all of the
parts of country has been done in this study. Although
referral/second opinion cases were also included in this
study so unusual cases such as AGCT were more com-
monly observed rather than Fibroma/FT as in many
previously done international studies. However in our
opinion this might not have affected the results to a
larger extent as the other unusual and complex tumor i.
e. SLCTs were encountered much less frequently as
opposed to international data.
One of the drawbacks and deficiency of our study was
unavailability of long term follow up of about half of the
patients, which might be required to see the exact recur-
rence rate and patterns of metastasis of ovarian sex cord
stromal tumors in our population [27-30].
Conclusions
The ovarian sex cord stromal tumors are rare ovarian neo-
plasms in Pakistani population. The relative frequencies
and patterns of presentation are more or less similar to
the international data, however Sertoli-Leydig cell tumors
were less frequently encountered. As the morphology of
sex cord stromal tumors vary widely, immunohistochemi-
cal studies are mandatory to exclude epithelial malignan-
cies, as the treatment option for the two, vary widely.
In future, there is need for long term longitudinal
studies to see the prognostic implications of various
subtypes and stage of these tumors.
Consent
Informed consent was taken from all the reported patients
with follow up.
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